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stroke, and should be regarded with the same degree of concern and 
importance as a stroke. TIAs are episodes of stroke symptoms that last 
only briefl y, and the causes are similar to the causes of ischemic stroke. 
Infarcts of the brain occur in 15-50% of  TIAs even though neurological 
signs and symptoms are absent.(3) The work-up of a patient presenting 
with a TIA or stroke should include routine laboratory tests (such as full 
blood count, urea and electrolytes, glucose, lipid profi le, prothrombin 
index and a coagulation screen) as well as an ECG, chest X-ray, cerebral 
computed tomography or magnetic resonance imaging (MRI) of the 
brain, and ultrasound or magnetic resonance angiography of the carotid 
and vertebral arteries. If these studies do not identify the source of 
ischemia, then investigations directed specifi cally at detecting a cardiac 
cause are appropriate. Cardiac causes of stroke include atrial fi brillation, 
abnormalities of the left ventricle and left atrium, valvular lesions, and 
cardiac procedures.(4) Detection of these latter problems involves the 
use of transthoracic or transoeophageal echocardiography (TEE), as 
well as ambulatory ECG monitoring for arrhythmias. 
The role of patent foramen ovale (PFO) and atrial septal aneurysm 
(ASA) in the genesis of ischemic stroke in young adults has been 
investigated extensively over the past 20 years.(5,6,7) Recently, the 
importance of PFO as an etiological factor for stroke or TIA in older 
patients has been highlighted.(8) 
Whilst patients with PFOs may present predominantly with neuro-
logical episodes, non-neurological events such as peripheral and 
pulmonary emboli may also occur.
The following report presents the Milpark Hospital experience with 
device closure of patent foramen ovale in 27 consecutive cases. The 
vascular event was considered the result of paradoxical embolism if the 
following conditions were met: presence of PFO with or without ASA 
with spontaneous or provocable (Valsalva maneuver) right-to-left 
shunting as assessed by TEE; clinically confi rmed stroke/TIA or other 
vascular event; and exclusion of any other identifi able cause.
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 Patent foramen ovale (PFO) is 
increasingly being documented in patients presenting 
with “cryptogenic” neurological and peripheral ischemic 
events.  Therapeutic options include the use of anti-platelet 
agents and in some cases non-surgical closure of the defect. 
In this article we present the Milpark Hospital experience 
of percutaneous closure of PFO to date.  The importance 
of looking for this defect is highlighted, particularly in 
patients presenting with recurrent events despite anti-
platelet therapy. Whilst routine closure of PFO is not 
advocated, it should be considered in certain select cases.
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Stroke is a syndrome encompassing a heterogeneous group of vascular 
diseases that lead to cerebral ischemia or hemorrhage. Conditions or 
factors that predispose to or increase the risk are diverse. Eighty-fi ve 
percent of strokes are ischemic and most ischemic strokes occur in 
persons older than 65 years of age in association with the develop-
ment of atherosclerosis. In contrast, younger patients with ischemic 
strokes often have few risk factors for atherosclerosis.(1) Approximately 
40% of ischemic strokes have no clear etiology and are therefore 
termed cryptogenic.(2) Transient ischemic attacks (TIAs) are a form of 
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Between November 2003 and March 2008, 27 patients underwent 
PFO closure at our centre. The demographic features of the patients 
are given in Table 1. There were12 males and 15 females with a mean 
age of 54.6 years. Eight patients had presented with a stroke and 
12 patients with TIAs. TIA was defi ned as a focal neurological defi cit 
resolving completely within 24 hours.  Three patients presented with 
deep vein thrombosis (DVT) and/or pulmonary embolism (PE) - one 
of whom had a history of multiple cerebral emboli that had not been 
investigated previously and another who had concomitant multiple 
strokes. Four patients presented with non-cerebral embolism. Of the 
12 patients who presented with TIAs, 6 had a history of a previous 
neurological event (2 prior strokes and the others prior TIAs) that had 
occurred up to ten years prior to the presenting event. One patient, 
who presented with a coronary embolus, gave a history of a stroke 14 
years earlier. Ten patients were on anti-platelet therapy prior to the 
presenting episode; 7 of them presented with TIA and 3 presented with 
non-cerebral embolism. It should be noted that the listed presenting 
event is not necessarily the indication for closure. 
A coagulation screen was included in the work-up of these patients. 
Two were documented to have anti-phospholipid antibodies. 
Seventeen patients had isolated PFOs and 10 patients had PFO with 
ASA. All device closures were with the Amplatzer PFO occluder (AGA 
Medical Corp, Plymouth, USA). The sizes used were 25mm in 
21 patients, 35mm in 4 patients and 18mm in 2 patients. All cases (with 
the exception of the fi rst two) represent the experience of two 
operators (CS and NP). For patient comfort the procedures were 
performed under general anaesthesia, with X-ray screening and TEE 
guidance; with the exception of the last 2 cases, which were done under 
local anaesthesia utilising intracardiac ultrasound guidance. PFO closure 
was carried out through the femoral vein. A multipurpose catheter was 
passed across the PFO and sited in a pulmonary vein (preferably the 
left upper vein). A stiff guidewire was then inserted and the multipurpose 
catheter exchanged for a long sheath, the tip of which is placed in the 
left atrium just proximal to the point of entry into the pulmonary vein. 
The PFO occluder, attached to the delivery catheter, was then inserted 
and advanced to the tip of the catheter and the distal (left atrial) disc 
deployed immediately beyond the catheter tip. The device and sheath 
were then pulled back to allow the left atrial disc to align against the 
septum. The right atrial disc was then deployed. After checking for 
correct placement the device was released from the delivery catheter. 
Coronary angiography was frequently done at the same time, 
particularly in the older subjects to exclude concomitant coronary 
artery disease. Patients are given clopidogrel for one month and then 
continued with low dose aspirin.  
TABLE 1: Demographic features of patients
Presenting eventGender
Follow-up
(months)
TEE
fi ndings
 38 M Stroke PFO 34
 50 M Multiple TIAs PFO 24
 45 M Multiple TIAs; initial TIA 4 years prior PFO 3
 50 F Stroke PFO 8
 51 F Stroke 10 years prior PFO & ASA 14
 76 F Embolus to hand PFO 6
 55 F Atrial fi brillation PFO 24
 38 M Coronary embolus: stroke  PFO 13
   14 years prior
 68 M PE and history of multiple  PFO 12
   cerebral emboli
 31 M TIA: coronary artery disease with  PFO 18
   stent 3 years prior
 58 M Multiple TIAs: CT scan multiple  PFO 20
   cerebral infarctions
 39 F DVT, PE & paradoxical embolism:  PFO 18
   anti-phospholipid syndrome
 51 F TIA PFO 12
 49 M Stroke 10 years prior PFO & ASA 15
 41 F Stroke PFO & ASA 10
 45 F TIA PFO 7
 71 F TIA: stroke 16 years prior following  PFO & ASA 11
   spinal surgery
 78 F Transient global amnesia:  PFO & ASA 10
   TIA 10 years prior
 76 F TIA PFO & ASA 12
 46 F Transient global amnesia PFO 2
 53 M Stroke PFO 2
 32 F Stroke PFO 9
 67 M Retinal artery embolism PFO 5
 59 M Pulmonary embolism PFO & ASA 3
 59 M TIA  PFO & ASA 2
 83 F Transient global amnesia PFO & ASA 1
 65 F Multiple strokes PFO & ASA 1
Age
No patient has been lost to follow-up. Twenty-seven patients have been 
followed for a mean of 11 months (range 1-34 months). One patient 
died one year after device implantation. He had had multiple strokes 
and died from an intracerebral hemorrhage following a fall. No patient 
has reported a recurrent neurological or embolic event. Three patients 
reported palpitations after device closure (one case of atrial fi brillation, 
and two with symptomatic atrial extrasystoles). In all 3 cases the 
arrhythmias had resolved within 6 months.
ILLUSTRATIVE EXAMPLES OF PATIENTS                     
A 71-year-old woman presented with recurrent TIAs. She had 
undergone spinal surgery sixteen years earlier. Two days postoperatively 
she suffered a stroke with infarction of the left parietal lobe confi rmed 
on computed tomography. Cardiac assessment at that time, including a 
transthoracic echocardiogram, was normal. The event was diagnosed as 
a watershed stroke thought to be due to postoperative hypotension. 
Over time she developed a short ejection systolic murmur. Four 
years later she presented with her fi rst TIA. Repeat transthoracic 
echocardiography documented mitral annular calcifi cation and 
calcifi cation of the aortic valve. She was treated with dipyridamole and 
aspirin. Thirteen years later she was reassessed by a neurologist 
following a TIA. She had a MRI scan of the brain which confi rmed the 
previous left middle cerebral artery infarct. She was advised to have 
a further cardiac evaluation. She then underwent a TEE which 
demonstrated a PFO with an ASA, with spontaneous right-to-left 
shunting. The defect was closed and she has had no further TIAs. 
There have been several reports of paradoxical cerebral embolism 
occurring during spinal surgery in the presence of a PFO.(9,10) We 
hypothesize that the original stroke was incorrectly ascribed to 
hypotension.  
A 76-year-old woman had a history of hypertension. In 2001 she was 
diagnosed with borderline hypertension. Her workup included a 
transthoracic echocardiogram which was reported as normal. Five years 
later she was confi rmed to have established hypertension and she was 
put onto anti-hypertensive therapy. A few months later she presented 
with an episode of confusion, subsequently diagnosed as an episode of 
transient global amnesia. She was investigated by a neurologist and an 
MRI scan performed and no specifi c abnormality was documented. She 
then underwent a TEE which demonstrated a PFO. The neurological 
episode was considered unrelated to the systemic hypertension, and 
more likely due to paradoxical embolism from the PFO.
An 83-year-old woman with established macular degeneration 
complained to her ophthalmologist of zigzag lines in front of her eyes. 
She had a history of longstanding obstructive pulmonary disease and 
systemic hypertension. The opthalmologist thought that the visual 
symptoms were not due to the macular degeneration and was 
concerned about the possibility of TIAs. She had carotid duplex studies 
which showed atherosclerotic disease but no signifi cant ulceration or 
stenosis. She was placed on statins and aspirin and advised to come 
back for a TEE. She presented a few months later with an episode of 
transient global amnesia. On TEE a PFO was documented. This was 
closed and no further visual symptoms have occurred. Despite the 
presence of the “usual” risk factors for stroke/TIA and concomitant use 
of anti-platelet therapy, this patient had further episodes, prompting the 
search for another cause.
A 49-year-old man presented with a stroke in his early thirties and was 
diagnosed with neurological sarcoidosis. His carotid angiograms were 
normal but a transthoracic echo showed an ASA. He was anticoagulated 
and remained on warfarin therapy. He subsequently developed diabetes 
mellitus and both hypopituitarism and blindness as complications of the 
sarcoidosis. He also had a previous signifi cant gastrointestinal bleed. He 
was deemed to be at high risk for continued warfarin therapy, prompting 
re-investigation of his ASA to establish whether a PFO was present. This 
in turn would allow for consideration of percutaneous closure, the 
discontinuation of anticoagulation and the use of low-dose aspirin as an 
alternative to warfarin. At TEE a PFO was documented in association 
with the ASA. The defect was subsequently closed percutaneously, and 
the warfarin therapy stopped. 
One patient aged 46 years had been previously diagnosed with epilepsy 
and treated for this. She had had extensive neurological investigations, 
including brain scans and electroencephalograms, all of which were 
reported as normal. Despite anti-epileptic therapy she continued with 
neurological episodes. She had three episodes of transient global 
amnesia, which warranted a referral for a disability medical evaluation. 
Assessment with TEE showed a PFO. At the time of closure, coronary 
angiography revealed a sub-total occlusion of the right coronary artery. 
This was not an anticipated fi nding and the patient had not undergone 
formal assessment for ischemia prior to the PFO closure procedure. It 
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was decided to intervene on the stenosis empirically, and a coronary 
stent was inserted. Post procedure the patient confi rmed that she had 
been experiencing episodes of angina-like chest pain.
A 31-year-old male had presented with a myocardial infarction at the 
age of 26 years that was thought to relate to the use of anabolic 
steroids. At that time, a right coronary artery stenosis was treated 
with stenting. He had been compliant with therapy including aspirin 
and statins. He subsequently presented to a neurologist complaining 
of headaches. A diagnosis of migraine was made, based upon his 
description of altered vision, which was thought to be a migraine aura. 
On closer questioning it was evident that these were episodes of 
amaurosis fugax. A TEE showed a PFO which was closed and no further 
TIAs (or migraines) have occurred. 
DISCUSSION                                                                       
The presence of a patent foramen ovale (PFO) has been shown to be 
associated with an increased risk of ischemic stroke.(5,6,7) While this 
association has been predominantly shown in younger patients with 
unexplained (cryptogenic) stroke, it has also been suggested to be a 
factor in older patients.(5,8,11,12)
Patent foramen ovale is associated with right to left shunting. The 
foramen ovale remains open in about one-fourth of the general 
population. The prevalence decreases with increasing age, from 34% 
during the fi rst three decades to 20% during the ninth decade.(13) 
The risk of paradoxical embolism increases with increasing size of PFO. 
With each decade of life the size of the PFO increases, so that the 
mean diameter in the fi rst decade is 3.4mm, whilst in the tenth decade 
the mean size is 5.8mm.(12,13) 
The role of PFO in the pathogenesis of ischemic stroke was suggested 
by a case controlled study in patients under 55 years of age with 
ischemic stroke detected by contrast echocardiographic examinations.(5) 
The prevalence of PFO was signifi cantly higher in the stroke group than 
in controls (40% vs. 10%; p < 0.001). Patent foramen ovale was found 
in 54% of stroke patients with no other identifi able cause. This study 
concluded that PFO associated paradoxical embolism was the cause of 
stroke. The subsequent PFO-ASA Study supported these conclusions, 
fi nding that 46% of young cryptogenic stroke patients had PFO.(14) It 
appears that patients with PFO have an increased prevalence of pelvic 
vein thrombosis.(15) In this study of young patients with cryptogenic 
stroke, pelvic vein thrombosis was more prevalent than in controls 
(20% vs. 4%). This may be the true source of the embolus with the PFO 
being the conduit that allows the embolus to cross to the systemic 
circulation. 
A prospective study of 598 patients (ages 18 to 55 years) presenting 
with cryptogenic stroke showed that 36% had a PFO, 1.7% had an ASA, 
and 8.5% had both abnormalities. Patients with both PFO and ASA 
who have had a stroke are at higher risk for recurrent stroke despite 
continued therapy with aspirin.(6,16) These studies excluded patients 
over the age of 55 years due to the higher prevalence of large 
vessel atherosclerosis in this age group. The association of PFO with 
cryptogenic stroke in older patients (those above 55 years) has only 
recently been reported.(8) Handke et al. have reported on the 
importance of PFO as an etiological factor in cryptogenic stroke in 
older patients. Their recent prospective study of patients with 
cryptogenic stoke compared with patients with stroke of known cause, 
looked at the prevalence of PFO with or without an associated ASA 
using transoesophageal echocardiography. They found that the 
prevalence of PFO was signifi cantly greater among patients with 
cryptogenic stroke than among those with stroke of known cause for 
both younger (43.9% vs. 14.3%) and older patients (28.3% vs. 11.9%) 
respectively. The association was more pronounced among patients 
with both PFO and ASA in both age groups (13.4% vs. 2.0% in younger 
subjects and 15.2% vs. 4.4% in older subjects). Multivariate analysis 
showed that the presence of PFO was independently associated with 
cryptogenic stroke in both age groups with odds ratio of 3.70 in the 
younger group and odds ratio of 3.00 in the older group.
Therapeutic options for patients with PFO with or without ASA, who 
present with a stroke or TIA include antiplatelet therapy with aspirin, 
dipyridimole or clopidogrel, oral anti-coagulation with warfarin, or 
closure of the defect surgically or percutaneously. Percutaneous closure 
of the defect is a well established procedure with a low complication 
rate in skilled hands. It is effective and associated with a lower rate of 
recurrent neurological events than medical therapy alone. This has been 
confi rmed in several observational studies and meta-analyses.(17,18,19,20,21)
Our reported series demonstrates the importance of taking an 
adequate history, and not always accepting an “obvious” pathology as 
the cause of the neurological defi cit or vascular event. These cases 
emphasise the need to reassess patients, particularly when symptoms 
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REFERENCES:occur despite apparent appropriate therapy. None of the cases had a 
PFO closed merely because of its presence. All patients had neurological 
symptoms or other embolic complications, many despite being on anti-
platelet therapy or oral anticoagulants. Most of the patients had 
recurrent events, often many years after the initial one. The term 
cryptogenic implies “hidden source”, a cause is not found. Although the 
link between TIA/Stroke and PFO/ASA is highly suggestive but still 
largely unproven, we suggest that the term “cryptogenic” only be 
considered after a TEE has been performed and a PFO, with or without 
an ASA, is ruled out. Long-term follow-up of a patient cohort like the 
one presented could give added support to such linkage. The work-up 
of a patient with TIA or stroke cannot be said to be complete without 
the performance of a TEE. Whilst this may be more imperative in the 
younger patient, older subjects should not be excluded.
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